TY - JOUR
T1 - In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia
T2 - A multicenter international randomized controlled trial (with video)
AU - Canto, Marcia Irene
AU - Anandasabapathy, Sharmila
AU - Brugge, William
AU - Falk, Gary W.
AU - Dunbar, Kerry B.
AU - Zhang, Zhe
AU - Woods, Kevin
AU - Almario, Jose Antonio
AU - Schell, Ursula
AU - Goldblum, John
AU - Maitra, Anirban
AU - Montgomery, Elizabeth
AU - Kiesslich, Ralf
PY - 2014/2
Y1 - 2014/2
N2 - Background Confocal laser endomicroscopy (CLE) enables in vivo microscopic imaging of the GI tract mucosa. However, there are limited data on endoscope-based CLE (eCLE) for imaging Barrett's esophagus (BE). Objective To compare high-definition white-light endoscopy (HDWLE) alone with random biopsy (RB) and HDWLE + eCLE and targeted biopsy (TB) for diagnosis of BE neoplasia. Design Multicenter, randomized, controlled trial. Setting Academic medical centers. Patients Adult patients with BE undergoing routine surveillance or referred for early neoplasia. Intervention Patients were randomized to HDWLE + RB (group 1) or HDWLE + eCLE + TB (group 2). Real-time diagnoses and management plans were recorded after HDWLE in both groups and after eCLE in group 2. Blinded expert pathology diagnosis was the reference standard. Main Outcome Measurements Diagnostic yield, performance characteristics, clinical impact. Results A total of 192 patients with BE were studied. HDWLE + eCLE + TB led to a lower number of mucosal biopsies and higher diagnostic yield for neoplasia (34% vs 7%; P <.0001), compared with HDWLE + RB but with comparable accuracy. HDWLE + eCLE + TB tripled the diagnostic yield for neoplasia (22% vs 6%; P =.002) and would have obviated the need for any biopsy in 65% of patients. The addition of eCLE to HDWLE increased the sensitivity for neoplasia detection to 96% from 40% (P <.0001) without significant reduction in specificity. In vivo CLE changed the treatment plan in 36% of patients. Limitations Tertiary-care referral centers and expert endoscopists limit generalizability. Conclusion Real-time eCLE and TB after HDWLE can improve the diagnostic yield and accuracy for neoplasia and significantly impact in vivo decision making by altering the diagnosis and guiding therapy. (Clinical trial registration number: NCT01124214.).
AB - Background Confocal laser endomicroscopy (CLE) enables in vivo microscopic imaging of the GI tract mucosa. However, there are limited data on endoscope-based CLE (eCLE) for imaging Barrett's esophagus (BE). Objective To compare high-definition white-light endoscopy (HDWLE) alone with random biopsy (RB) and HDWLE + eCLE and targeted biopsy (TB) for diagnosis of BE neoplasia. Design Multicenter, randomized, controlled trial. Setting Academic medical centers. Patients Adult patients with BE undergoing routine surveillance or referred for early neoplasia. Intervention Patients were randomized to HDWLE + RB (group 1) or HDWLE + eCLE + TB (group 2). Real-time diagnoses and management plans were recorded after HDWLE in both groups and after eCLE in group 2. Blinded expert pathology diagnosis was the reference standard. Main Outcome Measurements Diagnostic yield, performance characteristics, clinical impact. Results A total of 192 patients with BE were studied. HDWLE + eCLE + TB led to a lower number of mucosal biopsies and higher diagnostic yield for neoplasia (34% vs 7%; P <.0001), compared with HDWLE + RB but with comparable accuracy. HDWLE + eCLE + TB tripled the diagnostic yield for neoplasia (22% vs 6%; P =.002) and would have obviated the need for any biopsy in 65% of patients. The addition of eCLE to HDWLE increased the sensitivity for neoplasia detection to 96% from 40% (P <.0001) without significant reduction in specificity. In vivo CLE changed the treatment plan in 36% of patients. Limitations Tertiary-care referral centers and expert endoscopists limit generalizability. Conclusion Real-time eCLE and TB after HDWLE can improve the diagnostic yield and accuracy for neoplasia and significantly impact in vivo decision making by altering the diagnosis and guiding therapy. (Clinical trial registration number: NCT01124214.).
UR - http://www.scopus.com/inward/record.url?scp=84892578992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892578992&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2013.09.020
DO - 10.1016/j.gie.2013.09.020
M3 - Article
C2 - 24219822
AN - SCOPUS:84892578992
SN - 0016-5107
VL - 79
SP - 211
EP - 221
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
IS - 2
ER -